 |
Top 37 Alzheimer's Disease treatment startups
Feb 25, 2025 | By Jason Kwon | 22 |
Startups in the field of Alzheimer's disease treatment are developing innovative technologies such as precision medicine, gene therapies, immunotherapies, and neurostimulation techniques to target the underlying causes and symptoms of the disease.
1
Country: USA | Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
2
Country: USA | Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
3
Country: USA | Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
4
Country: USA | Funding: $295.1M
Acumen Pharmaceuticals is focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer’s disease.
Acumen Pharmaceuticals is focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer’s disease.
5
Country: USA | Funding: $280M
LEXEO Therapeutics develops gene therapy for the world's most devastating diseases
LEXEO Therapeutics develops gene therapy for the world's most devastating diseases
6
Country: USA | Funding: $269.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
7
Country: USA | Funding: $257.4M
Codiak Biosciences is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
Codiak Biosciences is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
8
Country: USA | Funding: $257.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
9
Country: USA | Funding: $225M
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
10
Country: USA | Funding: $180M
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
11
Country: Netherlands | Funding: €160M
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
12
Country: USA | Funding: $165M
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
13
Country: South Korea | Funding: $137M
D&D Pharmatech is a biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases.
D&D Pharmatech is a biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases.
14
Country: USA | Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
15
Country: USA | Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
16
Country: USA | Funding: $80.7M
Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.
Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.
17
Country: Denmark | Funding: $77.9M
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
18
Country: USA | Funding: $60.4M
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer's. We are driven by the belief that cognitive decline and conditions like Alzheimer’s disease can be beaten if detected early. Our energy and passion goes into developing digital tools to facilitate groundbreaking change.
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer's. We are driven by the belief that cognitive decline and conditions like Alzheimer’s disease can be beaten if detected early. Our energy and passion goes into developing digital tools to facilitate groundbreaking change.
19
Country: USA | Funding: $40.3M
T3D Therapeutics is a company developing remedial therapeutics for Alzheimer’s disease and other CNS disorders.
T3D Therapeutics is a company developing remedial therapeutics for Alzheimer’s disease and other CNS disorders.
20
Country: UK | Funding: $40.3M
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
